Suppr超能文献

维拉帕米对非胰岛素依赖型糖尿病患者葡萄糖耐量的改善作用。

Improvement of glucose tolerance by verapamil in patients with non-insulin-dependent diabetes mellitus.

作者信息

Andersson D E, Röjdmark S

出版信息

Acta Med Scand. 1981;210(1-2):27-33. doi: 10.1111/j.0954-6820.1981.tb09771.x.

Abstract

To study the effect of verapamil on the glucose tolerance and insulin response to oral glucose, 6 healthy subjects and 15 patients with non-insulin-dependent diabetes mellitus (NIDDM) were performed on separate days: 1) A standardized oral glucose load, 2) an identical glucose load during i.v. infusion of verapamil, and 3) a third oral glucose load after one week of oral verapamil treatment. No significant differences were found when the insulin and glucose responses with and without verapamil were compared. The patients with NIDDM were divided into three groups. Two tests were performed on separate days in each patient: group 1, a standardized oral glucose load and an identical glucose load during i.v. verapamil infusion; group 2, a standardized oral glucose load and a similar glucose load after one week of oral verapamil treatment; group 3, the protocol of group 2 was followed but oral placebo was given instead of verapamil. In groups 1 and 2, verapamil improved the tolerance for oral glucose, whereas the insulin response remained unaffected. In group 3, no significant differences were found in the insulin and glucose responses to the two oral glucose loads. These findings thus imply that verapamil improves the tolerance for oral glucose regardless of the route of verapamil administration in patients with NIDDM. They also indicate that this is accomplished by an effect of verapamil on other glucose regulatory factors than insulin.

摘要

为研究维拉帕米对口服葡萄糖耐量及胰岛素反应的影响,分别对6名健康受试者和15名非胰岛素依赖型糖尿病(NIDDM)患者在不同日期进行了以下操作:1)给予标准化口服葡萄糖负荷;2)在静脉输注维拉帕米期间给予相同的葡萄糖负荷;3)在口服维拉帕米治疗一周后给予第三次口服葡萄糖负荷。比较有无维拉帕米时的胰岛素和葡萄糖反应,未发现显著差异。将NIDDM患者分为三组。对每名患者在不同日期进行两项测试:第1组,给予标准化口服葡萄糖负荷并在静脉输注维拉帕米期间给予相同的葡萄糖负荷;第2组,给予标准化口服葡萄糖负荷并在口服维拉帕米治疗一周后给予类似的葡萄糖负荷;第3组,遵循第2组的方案,但给予口服安慰剂而非维拉帕米。在第1组和第2组中,维拉帕米改善了口服葡萄糖的耐受性,而胰岛素反应未受影响。在第3组中,对两次口服葡萄糖负荷的胰岛素和葡萄糖反应未发现显著差异。因此,这些发现表明,在NIDDM患者中,无论维拉帕米的给药途径如何,它都能改善口服葡萄糖的耐受性。它们还表明,这是通过维拉帕米对除胰岛素以外的其他葡萄糖调节因子的作用来实现的。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验